Figure 1.
KSHV-MCD clinical benefit response criteria laboratory variables. (A-D) Four indicator laboratory variables (A, C-reactive protein; B, albumin; C, hemoglobin; D, platelets) in the KSHV-MCD clinical benefit response criteria for 6 cycles (C1-C6) of treatment of all patients over all time points during the study. C1D2, cycle 1 day 2; EOT, end-of-treatment, 2 weeks after the last dose of tocilizumab on study.

KSHV-MCD clinical benefit response criteria laboratory variables. (A-D) Four indicator laboratory variables (A, C-reactive protein; B, albumin; C, hemoglobin; D, platelets) in the KSHV-MCD clinical benefit response criteria for 6 cycles (C1-C6) of treatment of all patients over all time points during the study. C1D2, cycle 1 day 2; EOT, end-of-treatment, 2 weeks after the last dose of tocilizumab on study.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal